Tech Company Inital Public Offerings
Hoth Therapeutics IPO
On 2/15/2019, Hoth Therapeutics went public.
Transaction Overview
Company Name
Announced On
2/15/2019
Transaction Type
IPO
Amount
$7,280,000
Proceeds Purpose
We intend to use approximately $5 million to $8 million of the net proceeds from this offering to fund the development of the BioLexa Platform for the treatment of eczema, including the commencement of Phase 2 clinical testing under the 505[b](2) regulatory pathway and the proof of concept study, should we determine to undertake such study. The balance of the net proceeds is expected to be used for other general working capital purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Rockefeller Plz. 1039
New York, NY 10020
USA
New York, NY 10020
USA
Phone
Undisclosed
Website
Email Address
Overview
Hoth Therapeutics (Nasdaq: HOTH) is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robb Knie
Browse more venture capital transactions:
Prev: 2/15/2019: Anaqua venture capital transaction
Next: 2/15/2019: Figma venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs